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Abstract 
Objective: Use of the New Psychoactive Substance (NPS) methiopropamine was first 
reported in 2011, but there are limited data on its acute toxicity. We report 11 patients 
presenting with analytically confirmed methiopropamine use. 
Methods: Adults presenting to 26 hospitals in the UK with severe acute toxicity after 
suspected NPS use were recruited from March 2015 to April 2018. Clinical features were 
recorded and biological samples analysed using tandem mass-spectrometry. 
Results: Methiopropamine was detected in 11 of 414 patients, with the last detection in 
August 2016. It was the only substance detected in one patient; other substances detected 
included other NPS in nine and conventional drugs of misuse in five. Common features 
included tachycardia (10/11), agitation (7/11), confusion (7/11), reduced level of 
consciousness (5/11), hallucinations (5/11) and a raised creatine kinase (7/11). Median 
length of hospital-stay was 17hours; ten were discharged without sequelae and one was 
transferred for in-patient psychiatric treatment. 
Conclusions: Methiopropamine was only detected during 2015 and 2016; most patients had 
other drugs detected, particularly other NPS. Raised CK was common but it is not possible to 
determine the degree to which this and other features could be contributed to by co-use of 
other substances.  
 
 
  
Introduction 
Methiopropamine (MPA, 1-(thiophen-2-yl)-2-methylaminopropane) is a synthetic 
methamphetamine analogue in which the benzene ring is replaced with a thiophene ring (Figure 1). 
It was originally synthesised in 1942 and previous in vitro work has shown that it is a reuptake 
inhibitor at dopamine and norepinephrine transporters with less effect on serotonin transporters.[1, 
2]  
 
 
Its use as a novel psychoactive substance (NPS) was first reported to the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) in January 2011; by November 2016, 
methiopropamine use had been reported in 14 countries worldwide.[3-6] In the UK 
methiopropamine was subject to a Temporary Class Drug Order on 27th November 2015 and 
subsequently controlled as a Class-B substance under the Misuse of Drugs Act, 1971 on 27th 
November 2017.[7] By early 2018 it was also a controlled substance in Belarus, Denmark, Estonia, 
Finland, France, Germany, Hungary, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, 
Slovenia, Sweden, Turkey, China and the US state of Florida.  
 
Although methiopropamine had been available online from UK-based Internet sites,[8] there are no 
published data available on the prevalence of use of methiopropamine from population or sub-
population surveys in the UK or elsewhere. Its use in the UK had been confirmed by the detection in 
pooled street urinal samples in London from March 2012 until June 2017 and other UK cities in April 
2014.[9-12] The UK National Programme on Substance Abuse Deaths (NPSAD) reported that 
methiopropamine was found in 16 post-mortem analyses in 2015, and thought to be implicated in 
the cause of death in 6 of these.[13] Methiopropamine was also reported in an Australian fatality in 
2015.[14] There are limited published data on acute methiopropamine toxicity – there have been 
only two previous reports of patients with acute recreational drug toxicity where methiopropamine 
was detected analytically.[15, 16] Here we describe a case series of eleven patients with analytically 
confirmed methiopropamine use.  
 
Methods 
The Identification Of Novel psychoActive substances (IONA) study is collecting and analysing 
biological samples from patients aged 16-years and older presenting to participating hospitals in the 
UK (26 sites as of June 2018) with pre-defined severe acute toxicity suspected to be due to NPS use 
[17]. These criteria include hyperpyrexia > 38.5oC, Glasgow Coma Scale (GCS) < 8, requirement for 
endotracheal intubation and/or critical care admission, seizures, psychosis or severe prolonged 
behavioural disturbance, tachycardia > 140/min or arrhythmia, systolic blood pressure >180 or <80 
mmHg, creatine kinase > 1000 IU/L, AST or ALT > 300 IU/L, hypoglycaemia, acute kidney injury, 
prothrombin time > 15 seconds, poisons severity score of 3 and any other severe manifestation 
suspected to be caused by exposure as determined and justified by the clinical team. Potential 
participants are identified by the clinicians managing them, who check that they meet these 
inclusion criteria and then obtain consent. Those unable to provide consent can be included on the 
advice of a personal (e.g. family member) or professional (e.g. health professional unconnected with 
the study) consultee, but consent is subsequently sought from the participant if and when they have 
recovered sufficiently. 
Residual biological samples (blood, urine and/or saliva) taken for routine clinical management were 
analysed by liquid-chromatography High-Resolution Accurate-Mass tandem mass-spectrometry, as 
previously described in detail. [17] Briefly, we used data independent Sequential Window 
Acquisition of all Theoretical fragment-ion spectra (SWATH) mass spectrometry (SWATH MS Sciex, 
Framingham, MA). This utilises the very fast scanning speeds of QqTOF mass spectrometers and 
repeatedly cycles through consecutive pre-set precursor ion isolation windows, detecting all 
fragment ion spectra from all precursor ions contained in a specific window at a given time, 
providing highly selective MS/MS mass spectra of all analytes. To identify unknown compounds we 
processed LC-MS/MS data using MasterView software version 2.2. (Sciex, Framingham, MA), 
identifying compounds by software-assisted library searching against reference spectra using 
LibraryView version 1.0 (Sciex, Framingham, MA) and ChemSpider Library version 2.0 (Royal Society 
of Chemistry, Cambridge, UK).  
 The IONA study has ethical and research governance approval.[17]  For this study, patients recruited 
to the IONA project where methiopropamine was detected were identified from the IONA database 
and demographic, exposure details, clinical features and outcome data were extracted, as supplied 
by the treating clinicians.[17] 
Case Series 
There were 414 IONA patients recruited from the launch of the study on 22nd March 2015 for whom 
analytical data was available by 20th June 2018. One or more novel psychoactive substances were 
detected in at least one sample from 235 (57%) of these, conventional drugs of misuse were 
detected in 352 (85%) and no drug of misuse was detected in 14 (3%). Methiopropamine was 
detected in 11 (2.6%) patients, including 7 of 55 (12.7%) recruited during 2015 and 4 of 172 (2.3%) 
recruited during 2016. Methiopropamine was not detected in any of the 187 cases recruited 
between September 2016 and 10th May 2018. It was detected in blood (7 patients), urine (1 patient) 
and both blood and urine (2 patients).  Median age was 24 (range 17-45) years; 9 (82%) patients 
were male. Cases were detected in London (4 patients), Liverpool (2), Newcastle (2), Blackpool (1), 
Edinburgh (1) and Manchester (1).   
 
The demographics, self-reported drugs used, analytical findings, clinical features and outcomes are 
summarised in Table-1. Methiopropamine was the only substance detected in one patient; other 
drugs detected in the remaining 10 patients included other NPS or their metabolites in 9 and 
conventional drugs of misuse in 5 patients; synthetic cannabinoids were the most frequent NPS and 
most frequent class of drug overall detected alongside methiopropamine with seven different types 
detected. The most commonly reported clinical features were tachycardia, agitation, confusion, 
hallucinations, mydriasis and seizures. Five patients had a GCS less than 15, of whom three had had a 
seizure. The most common blood abnormalities were mildly raised transaminases in 5 patients 
(range 68-349IU/L); and raised creatine kinase activity in 7 patients (range 152-189,836IU/L). Of 
these, 4 had “rhabdomyolysis” (creatine kinase > 5x upper normal limit), all with a creatine kinase 
>1000IU/L and two of these had evidence of serotonin syndrome (hyperpyrexia ≥38⁰C), hypertonia, 
agitation/severe confusion). Both required admission to an intensive care unit (level 3 bed) and 
intubation for management. Reported complications were acute kidney injury with a peak creatinine 
concentration of 1058mmol/L (patient 5) and pneumonia (patient 7).  Patient 3 was the only patient 
to have methiopropamine and no other drugs of misuse detected analytically. He presented 87 
minutes after smoking (no substance was reported). His only documented clinical feature was a 
tachycardia of 126 beats per minute, and he was discharged home after 2 hours. 
 
All patients survived to discharge from hospital with a median length of hospital stay of 16.5 hours 
(range 2-185 hours, IQR 4-90 hours); ten were discharged home and one was transferred for ongoing 
psychiatric treatment. The seven patients with a raised creatine kinase required a longer length of 
stay (median (IQR) 40 (7-138) hours, range 4-185 hours) compared to those who did not have a 
raised creatine kinase (median (IQR) 10 (3-17) hours, range 2-17 hours).  Two patients had a 
persistently raised creatine kinase and two had a persisting tachycardia at the time of discharge 
from hospital. 
 
Discussion 
 
We report the detection of methiopropamine in eleven (2.6%) of 414 patients with severe acute 
recreational drug toxicity suspected to be due to the use of NPS.  The clinical features seen in this 
series were predominately sympathomimetic in nature.  This is similar to the two previous case 
reports where methiopropamine was detected.[15, 16] The first reported case was in London, UK in 
2014 where a 27 year old woman presented 21hours after oral ingestion of “Hawaiian baby seeds” 
and nasal insufflation of “Quicksilver” powder with insomnia, intermittent palpitations, chest 
tightness, nausea and vomiting, dizziness, anxiety, euphoria, visual hallucinations, agitation and 
mydriasis; urine screening detected methiopropamine (400ug/mL) along with morphine, erginovine 
and metabolites of the synthetic cannabinoids JWH-018 and JWH-019.[16] The other case was in 
2016 where a 30year old man presented after smoking cannabis and ingested “synthacaine” with 
confusion, paranoid delusions, auditory and visual hallucinatory experiences and incoherent speech; 
the initial urinary immunoassay screening was positive for cannabinoids only. However toxicological 
analysis using LC-MS/MS detected only methiopropamine (plasma 14ng/mL; urine 8,160ng/mL).[15] 
 
All of the cases in which methiopropamine was detected in this series occurred prior to August-2016, 
with 8 before and 3 after methiopropamine was subject to a Temporary Class Drug Order in 
November 2015. No further cases have been detected in the IONA study since methiopropamine 
became controlled as a Class-B substance. [7] It is unclear as to whether legislation has had an 
impact on the frequency of detection of use of methiopropamine in patients presenting to hospital 
with acute toxicity, or whether its popularity has decreased as the variety of NPS available has 
increased.[18] None of the patients in our series in whom methiopropamine was detected had self-
reported the use of methiopropamine, although seven did report the use of an NPS. In the two 
previous case reports neither patient reported use of methiopropamine, although both reported use 
of an NPS.[15, 16] Previous studies have demonstrated that there is variation in the contents of 
NPS,[19-22] and it is possible that patients had inadvertently used an NPS or established drug that 
they were unaware contained methiopropamine. The clinical effects seen in this series are 
consistent with sympathomimetic exposure, although a limiting factor in this study is that co-used 
substances are likely to have contributed to these effects. Patient 11 only had methiopropamine 
detected in his urine, not his blood, suggesting that despite exposure to methiopropamine, his 
presentation with acute intoxication may not have been due to acute methiopropamine use. 
Another limitation of this study was that we did not have the resources to quantify the amount of 
methiopropamine detected in our biological samples. This study demonstrates the value of the IONA 
project in confirming the NPS involved in severe acute recreational drug toxicity presentations to the 
emergency department to determine trends in the NPS involved and consider the impact of 
legislative changes. It is likely that methiopropamine causes a sympathomimetic picture with a 
raised creatine kinase, although its frequent detection with co-used substances makes this hard to 
confirm. 
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Patient  1 2 3 4 5 6 7 8 9 10 11 
Age (years) 19 24 43 22 23 21 33 45 34 17 29 
Gender F M M M M F M M M M M 
Substances Reported Used  
(NR = not reported) 
New cannabis, 
LSD, Mushroom 
tea 
Poppers, 
Dusk till 
dawn 
NR NR Vertex Octagon, 
Ecstasy, 
Cocaine 
Pandora reborn Legal high Black chronic Party pills, 
cannabis 
Street drug 
Positive Methiopropamine Biological Specimens 
Tested 
Blood & urine Urine (no 
blood 
specimen 
received) 
Seru
m 
Serum Plasma Plasma Plasma Whole blood Serum Plasma Urine (not detected 
in plasma) 
Other NPS Detected 5F-PB-22, FUB-
NPB-22, 
Omberacetam  
FUB-PB-22, 
5F-AKB-48 
None 25I-N-BOMe, 
STS-135 
MDMB-
CHMICA 
2AI,  
AM-1248 
3F-
Phenmetrazine 
Ethylphenidate, 
Methylmethylphenidate 
5F-ADB, 2-AI, etizolam, 
3-fluorophenmetrazine 
None Omberacetam  
Classical Drugs Detected Citalopram, 
Diazepam 
Mirtazepine, 
Diazepam, 
Temazepam, 
Oxazepam, 
Paracetamol 
None None None Methadone Methadone, 
Benzocaine 
Diazepam, Citalopram Methadone, Diazepam, 
Norclobazam, MDMA 
MDMA, 
Methadone 
Methamphetamine, 
Gabapentin, 
paracetamol, 
quinine 
Clinical 
Features 
(Y = yes,  
N = no,  
NR = not 
reported) 
Hyperpyrexia (T > 38oC) N N N N 38.0 N 38.6 N N N N 
GCS (< 15) 9 N N N N 3 13 N 9 N 14 
Seizure Y N N N N Y N N Y Y N 
Mydraisis Y Y N N Y Y N N N Y N 
Hypertonia Y N N N Y N Y N N N N 
Hyperreflexia Y N N N N N Y N N N N 
Clonus Y N N N N N NR N N N N 
Dystonia N N N N Y N NR N N N N 
Tachycardia (BPM > 100) 120 135 126 125 N 130 130 111 101 127 140 
Hypertension (SBP > 160) 185 160 N N N N 167 N N N N 
Dizziness Y Y N N Y N N N N N Y 
Palpitations N Y N N N N Y Y N N N 
Breathing difficulties N Y N N N N Y N N N N 
Agitation N Y N NR Y Y Y N Y Y Y 
Aggression N N N NR N Y Y N Y N Y 
Confusion Y N N NR Y Y Y N Y Y Y 
Hallucinations Y N N NR Y Y N N Y N Y 
Paranoid Ideation N N N NR Y Y N N N N Y 
Other NR Bleeding NR NR Bleeding N Sweating Chest pain N N Headache 
Peak Blood 
results  
Acidosis (pH <7.35) 7.25 N N N N N N N N 7.06 N 
Lactic acidosis (lactate > 2mmol/L) N 5.8 N N NR NR NR N N 19.4 NR 
Raised creatinine (> 85umol/L) N N N NR 1058 N N N N N N 
Raised transaminases N N N NR 79 170 95 N 68 349 N 
Raised CK (>159 IU/L) 152 277 N 358 14687 70355 1715 N 305 189836 NR 
Prothrombin time (>13.2 seconds) NR N N NR 15 N 17 N NR 15 N 
Raised Urea (>8.3mmol/L) NR NR NR NR 15.3 NR 11.9 N NR NR NR 
MetHb (%) NR 37.6 NR NR NR NR NR N NR NR NR 
Table 1: The demographics, self-reported drugs used, analytical findings, clinical features, blood results and outcomes. All patients had methiopropamine analytically detected.  
Hyponatraemia (<135mmol/L) NR NR NR NR NR NR NR N NR 126 NR 
WBC (>11.0x109) NR NR NR NR 28 NR 24 N NR NR NR 
CRP (>5mg/L) NR NR NR NR NR NR 116 N NR NR NR 
Treatment Intubation and Ventilation N N N N Y N Y N N N NR 
Cooling N N N N N N Y* N N N NR 
Other (see below) N ** N N N *** **** N N N NR 
Overall Length of Stay (hours) 17 7 2 4 185 138 90 3 16 40 18 
Discharge 
outcome 
Home y  Y Y Y Y Y Y Y Y Y 
Psychiatry Inpatient  Y          
 
*External cooling by fan **Treatment with methylene blue *** Treatment with IV sodium bicarbonate **** Sedation
 
